Copper Radiopharmaceuticals for Theranostic Applications
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 889
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cu ions are essential for multiple biological processes and are indispensable in the maintenance of life. Cu is found in several effective compounds with anti-inflammatory and anti-proliferative properties and is involved in cancer development, angiogenesis, and metastasis. 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu are promising for molecular imaging applications. 64Cu is the most widely studied radioisotope for PET imaging and cancer therapy. Copper chloride (64CuCl2) is a radiopharmaceutical with theranostic capacity and simultaneous diagnostic and therapeutic abilities. 64Cu, with a half-life of 12.7 hours, decays by emission of β- particles, electron capture, and emission of β+ particles. The β+ can be used for PET imaging, and β- particles and Auger electrons emitted have therapeutic properties. 64Cu enters cells via the CTR1 enzyme, and it is distributed in different organelles. Then, ATOX1 transports it inside the nucleus, where it links to DNA. This aspect is essential for the theranostic application of 64Cu because it results in the Auger effect inside the nucleus with high LET and outside the nucleus with low LET. The direct link between 64Cu and the DNA chain allows for noninvasive and effective theranostic applications.
This Special Issue is dedicated to all efforts towards copper radiopharmaceuticals for theranostic applications.
Dr. Bianca Gutfilen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- copper radiopharmaceuticals
- copper-64
- copper-67
- copper-60
- copper-61
- copper-62
- PET
- theranostics
- molecular imaging
